Sangivamycin

Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an Ki of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers[1][2].

Product Specifications

CAS Number

[18417-89-5]

Product Name Alternative

NSC 65346; BA-90912

UNSPSC

12352005

Hazard Statement

H300

Target

Nucleoside Antimetabolite/Analog; PKC

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sangivamycin.html

Concentration

10mM

Purity

97.68

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=NC=NC(N)=C3C(C(N)=O)=C2)O1

Molecular Formula

C12H15N5O5

Molecular Weight

309.28

Precautions

H300

References & Citations

[1]Loomis CR, Bell RM. Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C. J Biol Chem. 1988;263 (4) :1682-1692.|[2]Lee SA, et al. The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation. J Biol Chem. 2007;282 (20) :15271-15283.